IGC

IGC is not a business you value on its financials — it's a single-asset clinical-stage wager on IGC-AD1, an investigational treatment for agitation in Alzheimer's dementia. The $1.27M of FY2025 revenue is incidental and, tellingly, shrank 5.5% YoY, so the headline P/S of 18.5x is a meaningless artifact; the entire $23.6M market cap is an option on the Phase 2 CALMA readout. The MD&A's interim data is genuinely encouraging — a ~71% (p=.012) week-2 and ~78% (p=.02) week-6 reduction in sleep disturbance on the NPI-12 subscale, plus an agitation signal (CMAI week-2 LS mean -12.19, Cohen's d 0.79, p=.071) approaching significance — and management touts ~$70K cost-per-patient versus a $100–150K industry norm. That is the bull case, and it is real but unproven: interim, small-n, and not yet a completed pivotal endpoint.

The disqualifier is the balance sheet. Cash fell 66% to just $405K while operating cash burn ran -$4.79M for the year — barely a month of runway. The company stayed alive purely on $4.4M of equity issuance in FY2025, and shares outstanding grew 10.9%. With a $121M accumulated deficit and only $6.33M of equity, IGC must raise again, imminently and from a position of weakness, at a $0.28 stock. Every financing round is dilution that transfers pipeline upside away from current holders, and the sub-$1 price plus micro-cap size point toward toxic or heavily discounted raises. Even a good trial can leave shareholders poorly rewarded if the cap table triples getting there.